Clinical Trial Results: Sildenafil Exercise: Role of PDE5 Inhibition [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial results for sildenafil as a PDE5 inhibitor assessing exercise-related outcomes in cystic fibrosis patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• SILDENAFIL (SILDENAFIL)

Snippet

Sponsor: National Jewish Health | Conditions: Cystic Fibrosis | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2026-08-28